Skin Cancer Treatment Journal
Subscribe
Sign in
Home
Notes
Archive
About
Latest
Top
It's Time to Retire 3.3 million: A Modern Estimate of the U.S. Skin Cancer Burden
Dermatology has quoted the same nonmelanoma skin cancer numbers for fourteen years. The population they describe no longer exists.
Jun 12
•
Adam Lefton
2
May 2026
The Most Common Cancer We Don't Count
Why there is no nonmelanoma skin cancer registry — and why it's time to build one
May 28
•
Adam Lefton
When Patient Stories Spark Unexpected Conversations
As Chief Marketing Officer of GentleCure, I’ve had the privilege of helping bring more than half a dozen patient stories to television.
May 9
•
Adam Lefton
1
April 2026
Patients Don’t Want a Procedure.
They Want a Cure.
Apr 27
•
Scott McKain
1
Making the Case to Preserve SRT
Why a less effective treatment may still have a role to play in the treatment of NMSC
Apr 21
•
Adam Lefton
1
Don’t Confuse the Device with the Treatment
GentleCure is Advanced IGSRT
Apr 12
•
Adam Lefton
1
Why IGSRT Represents a Meaningful Advancement Over Traditional SRT
If you can see the tumor, measure it, and confirm it’s gone… Why would you treat it blindly?
Apr 11
•
Adam Lefton
When Evidence Is Clear, Medicine Must Move Faster
Inertia Has Consequences, Speed Becomes Responsibility
Apr 5
•
Adam Lefton
March 2026
Policy and Patient Trust
Trust in healthcare is incredibly fragile
Mar 26
•
Scott McKain
3
1
When Doctors Stopped Leading
The Path Back to Trust
Mar 19
•
Adam Lefton
2
1
What Happened to the Hippocratic Oath?
Why Patients Are Paying the Price
Mar 14
•
Adam Lefton
7
When History Repeats Itself, Patients Pay the Price
This is the moment to break the cycle.
Mar 8
•
Adam Lefton
4
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
